After Hours Summary: SBUX -4.3% lower on weak guidance; MCD -6.6% as CDC confirms E. coli outbreak; LRN +22.8%, JBT +11.4%, TXN +3.5% higher on earnings; ENPH -9.6%, RHI -5.5% lower on earnings; ANRO -64% as Phase 2b study did not meet primary endpoint
After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: LRN +22.8%, JBT +11.4%, VICR +10.5%, EWBC +3.8%, PKG +3.8%, WFRD +3.6%, TXN +3.5%, ENVA +3.3%, RRC +2.2%, CNI +2.1%, TRMK +1.5%, MTDR +1.4%, BKR +0.5%, HIW +0.1%, RNST +0.1%
Companies trading higher in after hours in reaction to news: HRTG +2.2% (estimates Q3 catastrophe losses), QSR +2.2% (in sympathy with E. coli outbreak at MCD), WEN +1.7% (in sympathy with E. coli outbreak at MCD), BYON +0.4% (to reduce workforce by 20%), GOGO +0.4% (UP selects Gogo Galileo HDX fleetwide), SIRI +0.3% (increases dividend), PFE +0.2% (FDA approves ABRYSVO), UP +0.2% (UP selects Gogo Galileo HDX fleetwide), OMI +0.1% (enters into receivables purchase agreement), FBMS +0.1% (shareholders approve merger with RNST)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: ENPH -9.6%, RHI -5.5%, SBUX -4.3% (guides SepQ below consensus; global comps fell -7%; suspends FY25 guidance; increases dividend), MANH -4.2%, CSGP -3.8% (also to acquire Visual Lease), STX -3.5% (also increases dividend), PFSI -3.4%, BDN -1.8%, ADC -1.1%, VMI -0.5%, AGR -0.1%, NBR -0.1%, NTB -0.1%
Companies trading lower in after hours in reaction to news: ANRO -64% (Phase 2b study of ALTO-100 did not meet primary endpoint), MCD -6.6% (CDC confirms E. coli Outbreak), PRQR -5.5% (commences stock offering), SEDG -4.2% (in sympathy with weak ENPH earnings), LW -3.2% (in sympathy with E. coli outbreak at MCD), TSN -2.8% (in sympathy with E. coli outbreak at MCD), CYBR -2.5% (stock offering by selling shareholder), RUN -2.1% (in sympathy with weak ENPH earnings), DOUG -0.3% (CEO to retire, names new CEO), CAPR -0.2% (stock offering by selling shareholder), CX -0.1% (consortium comprised of Cemex and Linde to receive €157 mln in funding from the EU Innovation Fund), LLY -0.1% (Alzheimer's drug donanemab facing NHS block over cost, according to The Telegraph)